NCT02683824View on ClinicalTrials.gov

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 12, 2016

Primary Completion Date

September 27, 2021

Study Completion Date

December 1, 2022

Conditions
Healthy SubjectPancreatic Carcinoma
Interventions
DIAGNOSTIC_TEST

Computed Tomography

Undergo CT scan

OTHER

Laboratory Biomarker Analysis

Correlative studies

DIAGNOSTIC_TEST

PET/MRI scan

Undergo PET/MRI scan

DRUG

[18F]FP-R01-MG-F2

radioactive tracer

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Stanford University

OTHER

NCT02683824 - Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers | Biotech Hunter | Biotech Hunter